Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Weeks Treatment With Three Selected Oral Doses of BI 44847 as Tablet in Female and Male Patients With Type 2 Diabetes.
Phase of Trial: Phase I
Latest Information Update: 18 Jun 2014
At a glance
- Drugs BI 44847 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 13 Dec 2008 New trial record.